May 22, 2024: NCHR provided public testimony at the pediatric oncology subcommittee meeting regarding Section 504 of the 2017 FDA Reauthorization Act. We expressed concern that efforts to increase availability of new treatments for pediatric cancer have resulted in more planned studies but not in more treatments. We recommended sponsors prioritize engaging with key stakeholders such as the EMA Paediatric Committee, FDA Pediatric Review Committee, FDA Oncology Subcommittee of the Pediatric Review Committee, the Oncology Center of Excellence, and the use of independent Pediatric Expert Groups.
Read More »On Health Policy
Testimony of Dr. Diana Zuckerman, House of Representatives Small Business Committee
May 8, 2024: On behalf of NCHR, Diana Zuckerman’s testimony at the House Small Business Committee explains that FDA regulations save lives and saves patients’ financial security and do not interfere with innovation in healthcare.
Read More »Diana Zuckerman Comments on the U.S. Consumer Product Safety Commission Priorities for FY2025/2026
May 8, 2024: NCHR recommended that Consumer Product Safety Commission FY 2025-26 priorities include reducing exposures to PFAS and other chemicals, lead, and heavy metals in tire crumb used in homes, backyards, daycare, playgrounds, and artificial turf fields.
Read More »Dr. Diana Zuckerman Testimony at the House Small Business Committee Hearing
May 8, 2024: On behalf of NCHR, Diana Zuckerman’s testimony at the House Small Business Committee explains that FDA regulations save lives and saves patients’ financial security and do not interfere with innovation in health care.
Read More »NCHR Comment on Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products
April 29, 2024: NCHR backs FDA’s proposed guidance to collect standardized race/ethnicity data in clinical trials, which is crucial for addressing safety and efficacy disparities. We also urge a new category, mandatory implementation, and improved diversity to ensure accurate representation and meaningful efficacy and safety data
Read More »